1 Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL. 2 Department of Surgery, Tianjin Nankai Hospital, Tianjin, China. 3 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China. 4 University of Louisville School of Medicine, Institute for Cellular Therapeutics, Louisville, KY. 5 Division of Organ Transplantation, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL. 6 Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL. 7 Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Transplantation. 2017 May;101(5):1056-1066. doi: 10.1097/TP.0000000000001684.
Nonmyeloablative conditioning followed by donor bone marrow infusion (BMI) to induce tolerance has not been robustly tested in liver transplantation (LT) and may be unsafe at the time of LT. We hypothesized T cell-depleted BMI is effective in inducing tolerance when delayed after LT, resulting in potentially safer future clinical applications.
Nonimmunosuppressed syngeneic (Lewis to Lewis) and allogeneic (ACI to Lewis) rat LT transplants were initially performed as controls. Three experimental allogeneic LT groups were treated with tacrolimus (TAC) for 3 to 4 weeks and then underwent: (1) TAC withdrawal alone; (2) nonmyeloablative conditioning (anti-αβTCR mAb + total body irradiation [300 cGy]) followed by TAC withdrawal; (3) Nonmyeloablative conditioning + donor BMI (100 × 10 T cell-depleted bone marrow cells) followed by TAC withdrawal.
All group 1 recipients developed chronic rejection. Group 2 had long-term survival but impaired liver function and high donor-specific antibody (DSA) levels. In contrast, group 3 (conditioning + BMI) had long-term TAC-free survival with preserved liver function and histology, high mixed chimerism and blood/liver/spleen CD4 + CD25 + Foxp3+ regulatory T cells, and low DSA titers, similar to syngeneic grafts. While donor-specific tolerance was observed post-BMI, graft-versus-host disease was not.
These results support that donor-specific tolerance can be achieved with BMI even when delayed after LT and this tolerance correlates with increased mixed chimerism, regulatory T cell generation, and diminished DSA.
非清髓性预处理后输注供者骨髓(BMI)诱导耐受尚未在肝移植(LT)中得到充分验证,且在 LT 时可能不安全。我们假设在 LT 后延迟给予 T 细胞耗竭性 BMI 可有效诱导耐受,从而为未来更安全的临床应用提供可能。
非免疫抑制性同基因(Lewis 对 Lewis)和同种异体(ACI 对 Lewis)大鼠 LT 移植最初作为对照。三组实验性同种异体 LT 组接受他克莫司(TAC)治疗 3 至 4 周,然后进行:(1)单独 TAC 停药;(2)非清髓性预处理(抗-αβTCR mAb + 全身照射[300 cGy])后 TAC 停药;(3)非清髓性预处理+供者 BMI(100×10 T 细胞耗竭骨髓细胞)后 TAC 停药。
所有 1 组的受者均发生慢性排斥反应。2 组的受者长期存活,但肝功能受损,供体特异性抗体(DSA)水平升高。相比之下,3 组(预处理+BMI)在 TAC 停药后具有长期无 TAC 存活,肝功能和组织学正常,高混合嵌合体,血液/肝脏/脾脏 CD4+CD25+Foxp3+调节性 T 细胞,以及低 DSA 滴度,与同基因移植物相似。虽然在 BMI 后观察到供体特异性耐受,但未观察到移植物抗宿主病。
这些结果支持即使在 LT 后延迟给予供体特异性 BMI 也可以实现耐受,且这种耐受与增加的混合嵌合体、调节性 T 细胞生成和减少的 DSA 相关。